跳到正文
ECA GMP News·· 7 天前AI 评分74

FDA就组分检测、批次放行与质量监督缺陷向 Guangdong Bangze Medicine 发出警告信

FDA Warning Letter Highlights Component Testing, Batch Release and Quality Oversight Gaps

AI 导读

FDA在审阅依据FD&C法案704(a)(4)要求提交的记录后,于2026年10月26日向中国生产商 Guangdong Bangze Medicine Co., Ltd. 发出警告信,认定其药品生产控制不符合CGMP、属掺假产品,信函于11月3日公布。

正文 · 原文

The U.S. Food and Drug Administration (FDA) has issued a Warning Letter dated 26 October 2026 to a manufacturer in China, after reviewing records submitted under a section 704(a)(4) request. The letter was published on 03 November 2026.The agency found that the firm's drug products are adulterated under section 501(a)(2)(B) of the FD&C Act because its manufacturing controls do not conform to CGMP (21 CFR parts 210 and 211).The letter lists three main violations: Component testing: The firm did not adequately test the identity, purity, or strength of components. Incoming inspection records for several high-risk active ingredients and components lacked compendial identity, assay, and impurity testing, including the required limit tests. The firm also relied on suppliers' certificates of analysis without demonstrating the reliability of their test analyses. Some specifications referenced the Chinese Pharmacopeia instead of the USP. The FDA stressed that contamination of such ingredients has caused lethal poisoning incidents worldwide. Finished product release: Certificates of analysis for finished OTC products did not include identity, assay, or impurity results. They also showed no appropriate testing for objectionable microorganisms in each batch, which violates 21 CFR 211.165(a) and (b). Quality Unit (QU): The quality unit did not ensure CGMP compliance. Examples include the lack of an adequate ongoing stability program (21 CFR 211.166(a)) and insufficient qualification of a critical system (21 CFR 211.100(a)).FDA requires the firm to engage a consultant qualified under 21 CFR 211.34 to perform a comprehensive six-system audit and to verify the effectiveness of corrective and preventive actions. FDA may also withhold approval of new applications that list the firm as a manufacturer and may continue to refuse admission of its products under section 801(a)(3) of the FD&C Act.For further information, please see the complete Warning Letter to Guangdong Bangze Medicine Co., Ltd. on the FDA's website.

来源:ECA GMP News · gmp-compliance.org

事件后续 · 1

查看事件全部